{"id":"W4292148526","doi":"10.1212/wnl.0000000000201029","title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","year":2022,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Health and Medical Research Council; Canadian Institutes of Health Research; Sanofi Genzyme; MedDay Pharmaceuticals; Centre Hospitalier Universitaire de Rennes; EMD Serono; Multiple Sclerosis International Federation; Università di Catania; Agence Nationale de la Recherche; National Security Agency; European Committee for Treatment and Research in Multiple Sclerosis; Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Biogen; Celgene; Fondazione Italiana Sclerosi Multipla; Sanofi","keywords":"Discontinuation; Medicine; Fingolimod; Natalizumab; Multiple sclerosis; Internal medicine; Retrospective cohort study; Cohort; Pediatrics; Disease; Immunology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002689834,0.0002198259,0.0006245896,0.0007138664,0.0003137696,0.0008854079,0.0004629364,0.0006112357,0.0008150736],"category_scores_gemma":[0.009221443,0.0002429429,0.0006482688,0.0009046851,0.0002427348,0.0006401879,0.0004557019,0.0007752447,0.0001929532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002932414,"about_ca_system_score_gemma":0.0003024637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001681465,"about_ca_topic_score_gemma":0.001275959,"domain_scores_codex":[0.9981309,0.0006908593,0.0002204096,0.0004382458,0.0003196251,0.0002000756],"domain_scores_gemma":[0.9887531,0.0018366,0.007982766,0.0006224507,0.0004278223,0.000377207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003755049,0.00003296218,0.9977565,0.0000133405,0.00007379276,0.00004588954,0.00005183622,0.00002858808,0.00008160764,0.000006179098,0.00003262408,0.00150116],"study_design_scores_gemma":[0.00001727383,0.0001872566,0.9989719,0.000008647973,0.00005378805,0.0003882539,0.00005296641,0.0001443709,0.00005736179,0.00001309819,0.0001011882,0.000003869287],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987509,0.0007271827,0.00006233367,0.0000306666,0.000004288212,0.000008688569,0.0002307553,0.000004147171,0.0001809134],"genre_scores_gemma":[0.9994161,0.0001472327,0.0000483174,0.00001741856,0.00001117841,0.000006876458,0.0002945433,0.000001753737,0.00005655425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002689834,"threshold_uncertainty_score":0.01422542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.042825921262753,"score_gpt":0.2665634192110927,"score_spread":0.2237374979483397,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}